Loading organizations...
infinit Bio develops a cell-free biomanufacturing platform for the biosynthesis of high-quality psychedelic compounds. This technology is designed to enable a consistent and reliable supply of medicinal compounds to various stakeholders, including psychedelic therapy developers, clinical research organizations, and compassionate use programs. The organization is actively establishing a GMP-compliant facility to ensure its production capabilities meet regulatory standards. infinit Bio has garnered support from accelerator programs, notably being featured in the Antler Berlin Fall '21 portfolio, which was publicly revealed in April 2022. Specific details concerning funding rounds, valuation, employee count, or lead investors beyond Antler have not been publicly disclosed. The company positions itself within the burgeoning psychedelic medicine and mental health therapy sectors, aiming to address the demand for precisely manufactured compounds in this evolving field.
infinit Bio has raised $170K across 1 funding round.
infinit Bio has raised $170K in total across 1 funding round.
infinit Bio has raised $170K across 1 funding round. Most recently, it raised $170K Seed in April 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2022 | $170K Seed | — | Antler, South Central Ventures | Announced |
infinit Bio has raised $170K in total across 1 funding round.
infinit Bio's investors include Antler, South Central Ventures.
Infinity Bio is a Baltimore-based biotechnology company specializing in immune system profiling through its proprietary MIPSA (Molecular Indexing of Proteins by Self Assembly) platform, which enables high-throughput analysis of antibody-antigen interactions via DNA-barcoded sequencing.[1][2][3] As a service provider, it processes customer-submitted blood samples to deliver unbiased, multiplexed data on antibody reactomes—revealing immune responses to viruses, autoantigens, allergens, and environmental triggers—serving academic institutions, government agencies, and pharmaceutical companies in biomarker discovery, diagnostics, therapeutics, and research.[1][2][3] The company solves the challenge of scaling complex immunological data into actionable insights, with services like HuSIGHT™, VirSIGHT™, AllerSIGHT™, and the newly launched EnviroSIGHT™ for non-viral triggers; it recently raised an $8M Series A led by Illumina Ventures, acquired Serimmune's assets, achieved cash-flow break-even in its first year, and processes thousands of samples weekly from over 30 customers.[1][2]
Infinity Bio was founded in 2023 by Joy Nassif (CEO) and H. Benjamin Larman, PhD (associate professor of pathology at Johns Hopkins University), emerging directly from Larman's Laboratory of Precision Immunology at Johns Hopkins.[1][2][3] The core MIPSA technology, developed with NIH support, builds on decades of advancements in genomics, proteomics, immunology, and bioinformatics to transform antibody profiling into scalable sequencing workflows.[1][3] Early milestones included operationalizing a 9,000-square-foot lab in East Baltimore by late 2023, reaching cash-flow break-even within the first year, and profiling over 10,000 samples for the TEDDY study on type 1 diabetes triggers; visibility from events like JHTV’s Innovation Summit accelerated traction with biopharma and investors like Illumina Ventures.[1]
Infinity Bio stands out in antibody reactome profiling through:
(Note: Results distinguish Infinity Bio from unrelated entities like InfiniteBio (consulting), infinit Bio (psychedelics, 2021), or Infinite Biotech (safety testing).)[4][5][6]
Infinity Bio rides the rising wave of precision immunology and multi-omics, where antibody reactome data unlocks immune responses in health, disease, autoimmunity, infections, and environmental exposures—critical for next-gen diagnostics, targeted therapies, and biomarkers amid growing demands for scalable immune insights.[1][2][3] Timing aligns with post-2025 advancements in sequencing (e.g., Illumina ties) and surging biopharma needs for unbiased profiling, amplified by acquisitions like Serimmune and launches like EnviroSIGHT™ to address gaps in non-viral triggers.[1][2] Market forces favoring it include exploding interest in immune-mediated diseases (e.g., type 1 diabetes via TEDDY), NIH-backed tech translation from academia, and a shift toward service-based omics platforms that democratize complex data for diverse users, influencing the ecosystem by accelerating research pipelines and therapeutic development.[1]
Infinity Bio is poised to dominate antibody reactome profiling, leveraging its $8M raise for aggressive scaling, new services, and lab expansion to process even higher volumes while integrating Serimmune assets for a fuller immune intelligence suite.[1][2] Trends like AI-driven omics analysis, personalized medicine, and environmental immunology will propel growth, potentially expanding into GMP-grade applications or partnerships with big pharma for diagnostics/therapeutics. Its influence may evolve from service provider to platform enabler, fostering a "limitless" data ecosystem that powers breakthroughs in immune-related diseases—echoing its name and Johns Hopkins roots to redefine scalable biology.
